A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

NCT06625307 | Completed Phase 1

• 3 other identifiers: NN6537-7650U1111-1298-69222024-514431-18
• Study Type: interventional
• Target: 31
• Locations: 1 country
• Sites: 1

Brief Summary

The study is testing a new medicine to potentially treat people with heart failure. The main purpose of the study is to see if the new study medicine is safe and how it works in the body. It is the first time NNC0537-1482 (the new study medicine) is tested in humans and will be tested in healthy individuals (men and postmenopausal women). Participant will either get NNC0537-1482 or placebo (a "dummy medicine" without any active ingredients). Which treatment the participant get is decided by chance and the participant will only get either the study medicine or placebo on one occasion. It will be injected under the skin of the stomach by the study staff and the number of injections will depend on the cohort participant is assigned to. NNC0537-1482 cannot be prescribed by doctors. The study consists of 6 cohorts (groups) with 6 different dosing levels. The study will last for about 9 months. Participation in the study will last up to 42 days (depending on the cohort participant are assigned to) with an additional screening period that can be up to 28 days. Participant will have up to 10 visits to the clinic during the study period. However, the total number of visits depend on which cohort participant is assigned to.

Conditions

Healthy Volunteers; Heart Failure

Outcome Measures

Primary Outcomes (3)

• Number of treatment emergent adverse events (TEAE) in cohorts 1 and 2

  Number of events.

  From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 15

• Number of treatment emergent adverse events (TEAE) in cohort 3

  Number of events.

  From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 22

• Number of treatment emergent adverse events (TEAE) in cohorts 4, 5 and 6

  Number of events.

  From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 40

Study Arms (7)

NNC0537-1482 Dose level 1

EXPERIMENTAL

Participants will be administered a single dose of dose level 1 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

NNC0537-1482 Dose level 2

EXPERIMENTAL

Participants will be administered a single dose of dose level 2 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

NNC0537-1482 Dose level 3

EXPERIMENTAL

Participants will be administered a single dose of dose level 3 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

NNC0537-1482 Dose level 4

EXPERIMENTAL

Participants will be administered a single dose of dose level 4 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

NNC0537-1482 Dose level 5

EXPERIMENTAL

Participants will be administered a single dose of dose level 5 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

NNC0537-1482 Dose level 6

EXPERIMENTAL

Participants will be administered a single dose of dose level 6 of NNC0537-1482 subcutaneously.

Drug: NNC0537-1482; Drug: Placebo

Placebo

PLACEBO COMPARATOR

Participants will be administered a single dose of Placebo matched to NNC0537-1482 subcutaneously

Drug: Placebo

Interventions

NNC0537-1482 DRUG

Administered via subcutaneous route

NNC0537-1482 Dose level 1; NNC0537-1482 Dose level 2; NNC0537-1482 Dose level 3; NNC0537-1482 Dose level 4; NNC0537-1482 Dose level 5; NNC0537-1482 Dose level 6

Placebo DRUG

Administered via subcutaneous route

NNC0537-1482 Dose level 1; NNC0537-1482 Dose level 2; NNC0537-1482 Dose level 3; NNC0537-1482 Dose level 4; NNC0537-1482 Dose level 5; NNC0537-1482 Dose level 6; Placebo

Eligibility Criteria

• Age: 22 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or postmenopausal female.
• Age 22-55 years (both inclusive) at the time of signing the informed consent.
• Body Mass Index (BMI) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening.
• Considered eligible and generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

You may not qualify if:

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Use of prescription or non-prescription medicinal products, including herbal medications, within 14 days before screening. Occasional use of over-the-counter vitamins, or paracetamol or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain is permitted.
• Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than or equal to 20 millimetres of mercury (mmHg) or a decrease in diastolic blood pressure greater than or equal to 10 (mmHg) from supine to standing after 3 minutes, at the screening visit.
• Any laboratory safety parameters at screening outside the below laboratory ranges for:
• Alanine Aminotransferase (ALT) greater than (\>) Upper normal limits (UNL) plus (+) 10 Percentage (%)
• Aspartate Aminotransferase (AST) \> Upper limit normal (ULN) +20%
• Bilirubin \> ULN + 20%
• Creatinine \> ULN + 10%

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

ICON - location Groningen

Groningen, 9728 NZ, Netherlands

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Officials

• Clinical Transparency '(dept. 2834)'

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Sponsor staff involved in the clinical trial is masked according to company standard procedures
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 2, 2024
• First Posted: October 3, 2024
• Study Start: October 3, 2024
• Primary Completion: May 4, 2025
• Study Completion: May 4, 2025
• Last Updated: June 25, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share

Locations

NL (1)